शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSETransgene Biotek Ltd· Healthcare ServicesCriticalNegative
Announced Mon, 1 Sept, 2025 · 22:12 IST

General Intimation.

SEBI penaltyRegulatory & Legal View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-9.9%Reaction day
₹4.15
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-10.7% vs market
Healthcare Service Provider peers, median of 24sector+1.4%-11.3% vs sector

On the reaction day the stock moved 10.7 pts less than Nifty Microcap 250 and 11.3 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-9.9+0.8-10.7+1.4-11.3
Next day
-5.1+1.8-6.9+2.2-7.3
2d
-3.4+1.2-4.5+0.9-4.3
3d
-4.6+1.2-5.7+1.4-6.0
4d
-3.6+1.6-5.2+1.6-5.2
5d
-10.8+1.8-12.6+0.5-11.4
1w
-8.7+2.1-10.8+0.4-9.1
15d
-3.6+3.1-6.7-0.0-3.6
1m
+1.4+0.9+0.5-3.2+4.7
2m
-8.4+3.2-11.7-4.4-4.0
3m
-26.5-1.5-25.0-9.5-17.0
UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 24Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Transgene Biotek has informed BSE that M/s Babaji Nethralayya Private Limited has initiated Corporate Insolvency Resolution Process (CIRP) against the company under Section 7 of the Insolvency and Bankruptcy Code, 2016. The trigger is an unpaid secured loan that the company had raised with board approval to clear urgent liabilities. The company blames its failure to repay on ongoing restrictions and penalties imposed by SEBI and the Enforcement Directorate. Appeals pending before the Securities Appellate Tribunal (SAT) in Mumbai and the Appellate Tribunal in Delhi have not yet been resolved. The company has stated it will try to settle with the creditor to prevent the matter from moving to the next stage of the insolvency process.

Likely market impact

This is materially negative for shareholders — initiation of CIRP typically leads to a sharp drop in stock price, possible trading suspension, and significant risk of equity value erosion or dilution under a resolution plan. Investors should brace for high volatility and monitor NCLT hearings closely.